Ladies and gentlemen, thank you for standing by for The Sector Group's First Quarter 2025 Results Review. At this time, callers are in a listen-only mode. We will conduct a question and answer session later in the conference and review procedures on how to enter the queue to ask questions at that time. Should you require assistance during the call, please press 0 on your touch-tone phone. As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded. We'll begin by turning the conference over to Ralph Giacobbe. Please go ahead.

Great. Thank you, operator. Good morning, everyone. Thank you for joining today's call. I'm Ralph Giacobbe, Senior Vice President of Investor Relations. With me on the line this morning are David Cordani, Cigna Corporation's Chairman and Chief Executive Officer, Brian Evanko, President and Chief Operating Officer, and Ann Dennison, Chief Financial Officer. In our remarks today, David, Brian, and Ann will cover a number of topics, including our first quarter 2025 financial results and our financial outlook for 2025. Following their prepared remarks, David, Brian, and Ann will be available for Q&A. As noted in our earnings release, when describing our financial results, we use certain financial measures including adjusted income from operations and adjusted revenues, which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. A reconciliation of these measures to the most directly comparable GAAP measures, shareholders' net income and total revenues respectively, is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com. We use the term labeled adjusted income from operations and adjusted earnings per share on the same basis as our principal measures of financial performance. In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2025 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. Regarding our results in the first quarter, we recorded net after-tax special item charges of $229 million, or 84¢ per share. This included an after-tax special item charge of $163 million, or 63¢ per share, related to a strategic optimization program to further leverage the company's ongoing operational efficiency initiatives. Additional details of the special items are included in our quarterly financial supplement. Additionally, please note that when we make prospective comments regarding financial performance, including our full-year 2025 outlook, we will do so on a basis that includes the potential impact of future share repurchases and anticipated 2025 dividends. With that, I'll turn the call over to David.

Thanks, Ralph. Good morning, everyone. Thank you for joining today's call. We begin 2025 with momentum, and I'm pleased to report that in the first quarter, Cigna Corporation had strong results while we continue to focus on delivering on our commitments to build a better, more sustainable healthcare model. Joining me on the call is Brian Evanko, our President and Chief Operating Officer. I also want to welcome Ann Dennison, our Chief Financial Officer. As you likely saw, Brian and Ann were named to these new roles in March. With their announcement, we'll be following an evolved format for our call this morning. I'll share some brief comments and focus on our performance and how we're leading to address evolving stakeholder needs. Then Brian will discuss key business drivers fueling our growth, and Ann will provide more detail on our financial results. And then we'll take your questions. To start today, I'm pleased to report that we delivered $65.5 billion in total revenue, and we grew adjusted earnings per share to $6.74 this quarter. We are also raising our full-year EPS guidance estimate to at least $29.60. We delivered this performance in a dynamic environment with forces of change going beyond tariffs and trade, significant geopolitical, and evolving social impacts. At Cigna Corporation, our market-leading capabilities and flexible model have fueled our consistent track record of delivering differentiated value, innovating, and smartly expanding our addressable markets. Driving sustained long-term growth even in the most disrupted environments, whether measured over the last three, five, or ten years, we've performed and delivered on our EPS growth algorithm. We've been able to deliver these competitively attractive results through a relentless approach to position our company to lead through the forces of change in healthcare. We all know the healthcare system is on an…

Thank you, David. Before getting into our business performance, I'd like to share a few thoughts on the new roles that were announced in March for Ann and myself. I'm humbled and grateful to be named as President and COO of Cigna Corporation. My new team's primary focus will be on driving profitable growth for the company while making healthcare better for our primary stakeholders, most notably customers, patients, clients, and healthcare professional partners. I'm also thrilled to pass the reins of our finance function over to Ann, who is an accomplished and strategic financial leader. Over the past several weeks as I've transitioned to the new role, I have spent meaningful time meeting with a number of our clients and partners. And some key insights were reinforced through these engagements. First, our clients and partners consistently point to the attractive breadth and depth of our services and expertise across our EverNorth Health Services and Cigna Healthcare portfolio to solve their most pressing healthcare needs. For example, in EverNorth's specialty and care services businesses, representing about 30% of the company's income today, we have unique capabilities in this fast-growing sector that others can't match. Last year, we delivered more than 8 million prescriptions to over a million patients through our owned operational assets and capabilities, including safely mixing and preparing medications in sterile environments that take years to build and fully license. This business represents one of the company's top growth opportunities going forward. A space with high secular growth rates, specialty drugs are clinically intensive, serving a relatively small number of patients who rely on them. Our patients clearly value the experience enabled by our clinicians, pharmacists, and nurses, both in their home and over the phone, as we see 97% patient satisfaction rates on interactions with our Accredo…

Thank you, Brian, and good morning, everyone. I'm excited to join you for my first earnings call as the CFO of Cigna Corporation. Since joining the company over a year ago, I have been inspired by the dedication and talent of our employees, which gives me confidence in our ability to deliver value for our patients and customers and to achieve attractive long-term growth. I look forward to engaging with many of you over the coming months. As Brian mentioned, we started the year with a strong first-quarter performance ahead of expectations. Key consolidated financial highlights for the first quarter include: revenue of $65.5 billion and adjusted earnings per share of $6.74. With the first quarter results, we are raising our full-year 2025 adjusted earnings per share outlook to at least $29.60. This outlook reflects confidence in our businesses while maintaining a prudent view of the current environment. Now turning to our segment results. I will first comment on EverNorth. EverNorth continues to deliver strong results. First-quarter 2025 revenues grew to $53.7 billion, while pretax adjusted earnings grew 5% to $1.4 billion, in line with expectations. Specialty and Care Services showed strong growth with revenue up 19% to $23.9 billion. Normalizing for the impact of lower net investment income due to the absence of the VillageMD dividend, pretax adjusted earnings were up 11% year over year. This performance reflects the continued demand for specialty drugs, as well as increased adoption of biosimilars. Pharmacy benefit services also posted solid growth, reflecting strong client retention, expansion of existing relationships, and new business wins. Pretax adjusted earnings were up 4% to $544 million as our innovative capabilities continue to drive value and savings for our patients, customers, and clients. Overall, we're pleased with EverNorth's first-quarter results and confident about the long-term growth outlook…

Ladies and gentlemen, at this time, if you do have a question, please press 1 on your touch-tone phone. If someone asked your question ahead of you, you can remove yourself from the queue by pressing 2. Also, if you're using a speakerphone, please pick up your handset before pressing the button. One moment, please, for the first question. And our first question comes from Lisa Gill with JP Morgan. Your line is open. You may ask your question.

Thanks very much, and good morning. I wanted to start first with weight loss. You know, we saw a competitor yesterday signed a deal with Novo. I'm just curious around what you're seeing on the opportunity to be able to negotiate a better price with either of the large GLP-1 players in the marketplace? And then two, you talked about 9 million people enrolled in the program. But can you talk about general coverage from an employer or ASO perspective? Is there a big opportunity if we start to see materially better pricing? And then just lastly, David, I want to sneak this one in here. I just really would love to hear your thoughts on Arkansas and the legislation, and I believe you have a large pharmacy benefit relationship with one of the large employers in that state. So if you could give some color around that as well.

Lisa, good morning. You sure packed a lot in there. So let me ask Brian to take the first tranche of your questions, which I'll focus around the GLP-1 space and talk about what we're seeing in the market. You ask questions around what's happening with coverage, more specifically, what's happening with innovation in the marketplace, both in terms of the access and the affordability. Then I'll come back on the Arkansas bill. Alright?

Thanks, David. Good morning, Lisa. So if I step back and take a look at the GLP-1 space and our position, we're really proud of the comprehensive approach that we're taking towards the market. So that's represented by the combined suite of GLP-1 programs that I referenced in my earlier comments, specifically around EncircleRx, inReachRx, and then InGuide. We developed these programs really in response to some of the clear needs that were emerging around the market. So most notably, access, affordability, clinical safety, and longer-term lifestyle changes. And we don't necessarily see formulary placement or choosing one drug over another in this class as being sufficient to generate the societal impact that these drugs can have. Important to keep in mind that we have multiple formularies, multiple network options available across our EverNorth platform today. And some of these solutions are narrower in nature, some of them are broader. Now as it relates to specific drugs or manufacturers that we partner with, there are some principles that tend to guide us, whether for GLP-1s or for other drugs. So one principle is that competition tends to improve affordability over time. So that competition can occur between manufacturers on a specific type of drug or between injectable versions and tablet versions. All those dynamics are a good thing over time. It allows us to negotiate lower net costs, which benefit both clients and patients. Another principle is that choice is good, all else equal. And a final principle is to ensure that a resilient supply chain exists, such that there's adequate supply of any drug class. So these principles apply across most drug classes but are particularly important for GLP-1s. And we have a proven track record of being able to dynamically manage against this changing prescription drug landscape. So, again, we're really proud of our comprehensive approach to the GLP-1 market and the solutions that we've introduced that address access, affordability, clinical safety, and longer-term lifestyle changes. In terms of coverage levels, what we're seeing in our EverNorth book of business is just north of 50% of our employers provide coverage for weight management. That's relatively stable from where it was in 2024. In our Cigna Healthcare book of business, the percentage covering for weight management is lower. We're in the 15% to 20% range. That's because we have a smaller average employer in our Cigna Healthcare book of business. And that percentage is also relatively stable from 2024 to 2025. So as net pricing comes down in this class, it should increase the percentage of employers who are interested in providing this benefit for their employees and their dependents. David, you want to pick up on the last part of Lisa's question?

Sure. And again, before I move over to Arkansas, I'll just amplify two pieces. Lisa, first, as I think you very well know, back to coverage, part of your question, in the United States, the coverage levels. Broadly speaking, OECD countries outside the US do not cover GLP-1s for weight management. So our country is in a different posture. And hence, as employers at that stable coverage level are increasingly looking for more value out of the coverage, including continuity of care, as there's a lot of fracturing in terms of use of the medication starts and stops and starts and stops. So, just wanted to amplify that. Back to the Arkansas bill. First, context-wise for Arkansas, Arkansas, where the broad ticket portfolio is a smaller market for us. Now specifically to the bill, two points before I get into the Arkansas bill. As an organization, we have and will continue to operate in an active legislative regulatory environment. That's something we have a long track record of demonstrated engagement in, and then evolving our interest portfolio. Second, in that environment, we aggressively support the evolution of both legislation and regulation around, for example, transparency, but transparency that's actionable, improving value and affordability, and importantly, maintaining or expanding choice versus constricting choice. Specific to the Arkansas bill, we see it broadly speaking in opposition to these goals. Where the posture of the bill picks and chooses winners in the state, uses inappropriately from our point of view licensure capabilities to limit choice, commerce, and free market, the result of which, importantly, is going to be a decrease in access, a reduction in choice, an erosion in quality and continuity of care, and ultimately an increase in cost for citizens. So we oppose both the construct and the intent of the bill. Having said that, I'd reinforce that Arkansas is a relatively small market for Cigna Corporation. Lisa, thank you for your question.

Thank you. Next question comes from A.J. Rice with UBS. You may ask your question.

Hi, everybody. Thanks for the comments about the GLP-1s. I wonder if I could broaden it out a little bit. Obviously, there's a little bit more of an unsettled economic environment. I guess there's always some variability every time this year, but as you start to have discussions, obviously, you're well into the PBM selling season. And you're gearing up to talk about benefit design with your commercial clients and the broader healthcare coverage. What are you seeing in terms of where they're focused and things that they're asking you about? And I wondered in an unsettled economic environment, does that tend to drive more of that select market toward your product, or does it make them pause on making changes like that?

Morning, A.J. It's Brian. I'll take the question about the selling season, and then I'll try to address your point about the smaller employers and some of the dynamics in the economic environment right now. So maybe I'll start with the net results that we're expecting at this point in time for 2026, and then I'll unpack some of the market dynamics underneath. So within our Express Scripts pharmacy benefits services business, we're currently tracking toward mid-nineties or better retention. That's a strong retention level consistent with what we've seen in prior years. Within the Cigna Healthcare portfolio, it's still pretty early in the season for smaller employers, but we do have some good insights on the larger end of the market, specifically our national accounts business. And here, we continue to view this market segment as one that'll be a flat to shrinking market overall. Over time, and our strategy in the national account space is to maintain our current share. And at this point, we're not seeing anything unique for 2026 that would cause us to deviate from that general pattern. So maybe I'll spend just a minute or two on some of the dynamics transpiring in this selling season. Your question. So I'd characterize this as an active season both as we compete for potential 2026 new business but also amongst our existing client base who are exploring the market. So in terms of some common themes, a few things I'd highlight, as we've discussed on prior calls, affordability continues to be a key area of focus for employers, particularly with the higher cost trend environment that we're experiencing. Now this is driven in part by the wave of drug innovation, including specialty drugs and GLP-1s, along with continued growth in mental health spending. Now fortunately, the…

Thank you. Our next question comes from Justin Lake with Wolfe Research. You may ask your question.

Thanks. Good morning. I wanted to follow-up on the stop-loss discussion. I was hoping you might be able to give us a little more detail in terms of what you're seeing in terms of cost trend in your commercial book, but specifically in the stop-loss business relative to what you saw kind of pressure you in the fourth quarter. And then any early feedback from the customer community as you're starting to work on getting that book repriced for 2026. I know you're trying to target getting it fully back in terms of the margin that you lost last year, but you've guided it to something a little bit less than that. Curious how you're seeing that kind of run through. Thank you.

Justin, good morning. It's David. Let me ask Brian to start with the marketplace, our rate execution, continue working with our clients, etcetera. And then Ann will pick up from there and talk about performance we saw in the first quarter to bridge a part of your latter part of your comment, our plan and expectation is to recoup the margin through the 2025-2026 season. So over the two-year horizon, profitable book of business, less profitable than it's historically been. We'll recoup throughout the course of this year, largely in the second half, and then recoup further in 2026. Brian, can I just talk about the selling season and the client's reactions?

Sure, David. Good morning, Justin. So the headline I ask you to take away is that we're tracking to the stop-loss margin improvement plan that we outlined during the fourth-quarter call. Now kind of stepping back from that, our stop-loss offerings are an important part of our US employer portfolio within Cigna Healthcare. They work in complement with our other products and solutions for the employers who choose to employ a self-funding or ASO style relationship with us. And the stop-loss products provide employers with budgetary protection against unexpected large claim activity or aggregate cost levels being unexpectedly high. And all of the stop-loss business that we write is through an integrated offering with the employer where we also administer their overall medical benefits. And we continue to see very strong market demand for these solutions. And we are the industry leader in this space. Now as we noted in our fourth-quarter call, we are working to improve the margin profile in this business over the course of the two renewal cycles as David indicated, and we're confident in our ability to deliver against this. Now over the past few months, we've been able to make progress on this plan specifically by incorporating the revised cost structure into our later 2025 client renewals, and we've been able to execute this while preserving our typical client retention levels. So overall, the year-to-date '25 performance is tracking to the expectations that we had outlined for you during the fourth-quarter call. I'll turn it over to Ann if you want to elaborate on what we're seeing in the first-quarter financials and the outlook specifically.

Sure. Thanks, Brian. So we'll start maybe first with trend utilization, what we're seeing more broadly, and then talk about stop-loss specifically how the first quarter has played out. So heading into 2025, we expect the trend to remain elevated. In the first quarter, trends remained elevated in most categories consistent with what we expected. So we continue to see elevation in the specialty and behavioral categories. As I mentioned in my prepared remarks, we did see some moderation in surgical activity and OB services. But given it's early in the year, we've prudently maintained our MCR assumptions for the full year. Now specifically for stop-loss, as a reminder, we've assumed a higher stop-loss MCR for this year versus last year, consistent with what we said coming out of the fourth quarter. Stop-loss is a cumulative product, and we are still very early in the year. The first-quarter stop-loss MCR reflects our expectation for the full year. So thus far, things are tracking to expectation based on the early indicators that we're monitoring to measure the performance of the business. So taken altogether, as Brian said, performance is in line with our expectations for the stop-loss book.

Thank you. Our next question comes from Charles Rhyee with TD Cowen. Your line is open. You may ask your question.

Yes. Thanks for taking the question. Just wanted to follow-up maybe on Arkansas for a second. What is the recourse for companies like Cigna and other companies that operate both PBMs and, you know, pharmacies, and in this case, maybe mail-order specialty pharmacy? Because I think, obviously, the bigger question is perceptions of potential conflicts of interest of having these kinds of entities joined together. And, you know, obviously, there's a lot of different proposals, both in Congress and across many states, trying to address this through things like greater transparency. And, you know, and I appreciate that you guys have been moving forward and trying to provide greater transparency. But, you know, what are, in your view, some of the more simple steps that could be done to maybe assuage some of these concerns about potential conflicts of interest that doesn't have to go all the way to what Arkansas has tried to do here? And then if I could just quickly add also, if Qualen has launched biosimilars to Stelara, it would be great. Thanks.

Good morning, Charles. It's David. I'm gonna give you a directional tone to your question because I'm not trying to give you the specifics you may be looking for. First, as I mentioned to Lisa's question, we fundamentally think the bill is a flawed posture. The value creation is indisputable of what is being able to be delivered and supported. And actually, to bridge your last comment and work my way back, if you think about the biosimilar success in terms of the interchangeable that we've been able to launch and bring to market for Humira, that is enabled by the breadth of our portfolio and the breadth of our capabilities. It's been able to harness those. The result of which is significant savings for employers, health plans, or government latency clients in $0 out of pocket for a consumer. It's indisputable. Secondly, as an example, the capabilities Brian walked through around our GLP-1 innovations, they are expressly enabled by harnessing the breadth of capabilities across our portfolio, as opposed to dismantling those. So fundamentally, we disagree with the core tenant. Now back to your point. What can be done? Fact-based engagement relative to what the problem statement is, how the marketplace works, and how ongoing innovation is being brought to market. Second, further amplifying and activating client's voice relative to maintaining choice as opposed to structurally removing choice. Third, as you articulated, and I highlighted in my prior comments, embracing transparency. Transparency is something that the marketplace has and further leans into. In fact, we think about the pharmacy services space. You have the largest, most sophisticated buyers in the marketplace from Fortune 1000 corporations to large, diverse health plans through integrated healthcare delivery systems, through governmental agencies themselves. The last two comments I would make are to continue to innovate, continue the innovation of our products, programs, services. And then finally, taking necessary steps from a regulatory or litigious standpoint if we deem all else fails because we fundamentally disagree with this posture, which, again, removes choice, arbitrarily picks winners and losers, and erodes affordability, clinical quality, and access for consumers. I think on the back end, you were asking a little bit about what the status of the Stelara biosimilar is. So I'll turn it to Brian and ask him to highlight the rate and pace of that other, again, very exciting evolution of our portfolio.

Sure, David. Good morning, Charles. I don't think I have anything else to add on the Arkansas issue. But as it relates to Stelara biosimilar, kind of stepping back from that, we're pleased to see the building momentum of biosimilars in the US, which really was powered forward by Humira biosimilars becoming more prevalent. And as a reminder, this is just the start of a multiyear wave that's coming here for US-based biosimilars. And beyond Humira, we expect another $100 billion of specialty drug spend to be subject to competition for and generics by 2030, which represents a tremendous opportunity to reduce net costs for patients and clients. As I mentioned earlier, we'll have a $0 patient out-of-pocket biosimilar option available for Stelara starting this month. And that leverages the learnings that we had from the Humira biosimilar that we launched last year. Now importantly, each biosimilar will have different rates of adoption based upon factors such as interchangeability, dosage levels, branded alternatives, and other dimensions. But that said, we do expect to see gradual growth in Stelara biosimilars over the balance of the year. And our EverNorth outlook contemplates this. We'd expect a further step up in 2026. Thanks for the question.

Thank you. Our next question comes from Ann Hynes with Mizuho Securities. Your line is open. You may ask your question.

Hi. Thank you. Good morning. Just on the capital deployment front, I know you've said in the past that bolt-on M&A is your priority. Is that still the case? And on that front, are there any capabilities that you think you need either in the health insurance segment or EverNorth that you need to invest into organically or inorganically? Thank you.

Ann, good morning. It's David. There's two dimensions to your question. One is our capital deployment strategy and specifically within it, the M&A dimension that comes along with it. Specific to our capital deployment strategy, that remains consistent. Priority one, support the ongoing growth of the business. Priority two, prudent deployment of capital for CapEx and innovation. Priority three, return excess capital to shareholders and/or pursue attractive M&A, which I'll come back to in a moment relative to those criteria. As it relates to our actions, as you see, we've been meaningfully returning excess capital to shareholders through repurchase as well as an attractive dividend that we just recently raised again. Now specific to M&A, our priorities remain consistent. We look for opportunities that are strategically attractive assets. Second, assets that are financially attractive. So within that, we see durable synergies that would inure back to us as we would be able to execute. And then certainty in terms of being able to close the asset. As an organization, we've been oriented around bolt-on acquisitions. We typically use that terminology with our size and scale to connote acquisitions up to single-digit billions of dollars. So that gives you an idea of size and scale, and we don't identify or highlight any specific category or capability. I think the last piece may be inferred in your comment is do we believe we have to add on any capabilities? I would say relative to that answer is no. We feel very good about our business portfolio and the positioning. We've been quite deliberate to position our business portfolio. And as we stand today, a high-performing modular services portfolio through EverNorth, and we have a high-performing integrated benefits portfolio that addresses both US and non-US opportunities through Cigna Healthcare. And our track record is quite clear relative to its ongoing growth. Final comment I would make is we've been quite deliberate in terms of ensuring that we're well-positioned into a variety of addressable markets. From the individual market through employers, health plans, governmental agencies, and increasingly integrated delivery systems and multi-specialty physician groups with our broad portfolio of services. So capital deployment strategy consistent, M&A priorities consistent, focused on bolt-ons where they make strategic financial, and clarity of closed sense. Thanks for your question.

Thank you. Our next question comes from Andrew Mok with Barclays. Your line is open. You may ask your question.

Hi, good morning. As the Part D market evolves alongside the IRA, curious to hear what your experience has been on the EverNorth side of the business. Can you comment on any manufacturer or member behavior that you're seeing in the market? And relatedly, are you seeing a pickup in specialty or high-cost brand scripts from the Part D program that were previously served directly through a patient assistance program? Thanks.

Morning, Andrew. It's Brian. So I'll try to take both parts of your question there. So as you know, we've spoken a number of times about drug innovation being an emerging trend in healthcare, which is poised to continue through at least the end of the decade. In the specialty drug space, the core of your question, this is already a $400 billion addressable market with high single-digit secular growth moving forward. And within that specialty drug space, we are the leader in this clinically intensive business, which positions us uniquely to create value for the patients that we serve. Now those dynamics certainly transpired during the first quarter. So when you think about our 19% growth in the Specialty and Care Services business, that was powered by all of the themes I just made reference to. And in the quarter, our EverNorth specialty script volumes, they were up mid-teens. And the most notable growth within that was in our Medicare book of business, which showed a considerably higher rate of growth in comparison to the commercial employer or the Medicaid books of business. Now it's not 100% clear to us whether some of that Medicare growth was specifically induced by the IRA via the lower out-of-pocket maximums for the Medicare Part D plans or by pharmaceutical manufacturers ramping up their marketing to prescribers. But what is clear to us is that there's been a structural shift in the US healthcare space toward more complex clinically intensive specialty medications. And our EverNorth specialty and care services business is a clear beneficiary of this substantial growth in specialty drug utilization. And you saw this again in the strong first-quarter results along with our long-term average annual income growth expectation of 8% to 12% for this high-growth part of the healthcare system. Thanks for the question.

Thank you. Our next question comes from Erin Wright with Morgan Stanley. You may ask your question.

Great. Thanks for taking my question. Could you describe a little bit more about inReach as well as the InGuide pharmacy role and what these initiatives entail and the economics for Cigna and just on the GLP-1 strategy? I know the category is unique, but what are the tools or how are the tools different compared to what was deployed across historically PCSK9s, hep C, I guess, how do we compare, or how is this different in terms of the strategy to address drug cost turn across your customer base? Thanks.

Good morning, Erin. It's Brian. I'll try to take those different components here. So as I made reference to earlier, we're proud to take a leadership role here around GLP-1s, which as we all can appreciate, this is an impact that impacts many dimensions of our society. And GLP-1s really are a microcosm of the broader wave of drug innovation that's transpiring that I just made reference to in Andrew's question. So we stepped back from this. We saw an opportunity to create new value in the GLP-1 space through the combination of addressing access, affordability, clinical safety, and longer-term lifestyle changes. And as it relates to our Encircle, inReach, and InGuide suite, maybe I'll just spend a moment talking about the market needs that are underneath those themes that I just made reference to. So many of our employer clients, they've indicated the desire to offer GLP-1 coverage for weight management, but those employers are concerned about the cost and safety impact of unfettered access to the drugs. And as time unfolded, we also saw that adherence to the drugs was mixed, with people starting and stopping, and many patients were concerned about access disruptions. So those dynamics were leading to some patients stockpiling their GLP-1s, some others were resorting to microdosing. All of those things can distort the clinical effectiveness of the drugs. And an additional market dynamic that we saw was that pharmacies were reluctant to dispense the drugs because of their own economics, which exacerbated some of the concerns about access to the drugs. So we introduced EncircleRx in early 2024 as a mechanism to provide some budget certainty for employers along with addressing patient safety and supply concerns. And there's been really strong demand from our employer base here, with we now have 9 million people eligible for the program. And we built upon this this year through the introduction of the inReach solution that I made reference to. You can think about this as an enhanced clinical support and reimbursement stability model for participating pharmacies. So think about a curated network high-touch clinical support for patients. And importantly, the clinical support includes things like dose optimization, patient education, fraud, waste, and abuse monitoring. And in conjunction with that program is our InGuide solution, which is our specialized home delivery GLP-1 pharmacy for those patients who prefer to have the drugs delivered directly to their home. So taken altogether, the suite of EncircleRx, inReach, and InGuide is meant to address these societal challenges of access, affordability, clinical safety, as well as longer-term lifestyle changes. Now the financial contribution to that part of the question you should think of this as certainly embedded in our EverNorth outlook for the year. One of many things that contributes to the overall P&L. But importantly, the steps we took here were meant to address those societal needs around this important drug class.

Thank you. Our next question comes from Josh Raskin with Nephron Research. Your line is open. You may ask your question.

Hi. Thanks. Just a quick clarification. What percentage of your select segment actually takes stop-loss with the ASO versus a full-risk solution? And then my bigger question is just in the past, you've spoken about the disrupted environment for Medicare Advantage, and I'd be curious to get your thoughts on the segment currently and perhaps how the 2026 rate notice is impacting your forward view with an understanding, obviously, that you're not no longer in the business as of a month and a half ago.

Morning, Josh. I'll take the first part of the question and David will take the second. So as it relates to the select segment and the funding mix, as I made reference to in an earlier question, we're agnostic. So employers can choose which model they like. And amongst the 3 million or so clients that we have there, you can think of it as a little bit over half in a fully insured and a little bit under a half in an ASO, and those that pick an ASO are self-funded. Essentially, a percentage of them are buying stop-loss protection around that because given the size of their respective employee base, they need the budgetary protection certainty that comes with our stop-loss offerings, whether that be individual or aggregate. David, do you want to take the second part of Josh's question?

Sure, Josh. Good morning. As you noted, we exited the space at the first quarter. I think broadly you're asking our point of view relative to where the space is and where it's going. First and foremost, as I said multiple times, we believe in the importance of strength of an overall value of the MA offering in the marketplace. We should continue to inspect that. The growth there has been indisputable. Therefore, the value of seniors see is quite significant. Secondly, on average, lower average income levels for individuals who are buying that, meaning price sensitivity yet higher value. And greater clinical coordination across the players that exist. Now, importantly, before I specifically comment on the rating environment you're asking about, we serve a meaningful number of Medicare Advantage customers, whether it's through MA, MAPDP, standalone PDP, duals, or otherwise through our broad portfolio of EverNorth services. Indirect service of other health plans, as well as Brian referenced, the breadth of what Accredo provides day in and day out. So now bridging back to the last part of your question, the overall rate environment obviously is strained. The V28 phase-in environment is causing strain to some of the ecosystems to try to get the right symmetry between benefit offering and pricing. What we see in that, my last comment would be, those that are in the marketplace are even pressing more for value and affordability. And some of the innovations we bring are directly responsive in support of our health plan clients today. Help them have the value of the clinical continuity in support of SARS. As well as the overall affordability and value that's going to be necessary on a go-forward basis. Josh, thanks for the question.

Thank you. Our last question comes from George Hill with Deutsche Bank. You may ask your question.

Yes. Good morning, guys, and thanks. Kind of just two housekeeping questions. Ann, on the 100 basis points that was the in MLR that was the contribution from the MA business, I guess, can you say whether that was a like, was that was the carrying of that business a net drag on earnings in the quarter? And can you kind of quantify what the net drag or the net contribution was in the quarter? And then I also thought for the guidance for fiscal 'twenty five, that you guys had some degree of what I'll call a recession assumption in the numbers. And I'd like to just I'd like like kinda your updated comments around how you're thinking about that.

Great. Thanks for the question. I'll take the first part of the question and turn it over to David for the second part. On the Medicare business, as I said in my prepared remarks, that extra month increased our MCR by about 100 bps as the Medicare business ran at a higher rate, ran at a higher medical care ratio. The impact on earnings was marginal. I think less than $20 million. The favorability really came from our ongoing businesses. So and we saw favorability both in earnings and embedded in the MCR for the ongoing businesses.

So, Ann, picking up before I go to the economy, the net effect of that would be ongoing businesses in Cigna Healthcare. Think about the MCR at about 80. Absent the impact of the Medicare Advantage component. And the approximate $20 million, a little less than $20 million is the result of having that business for about a month longer than we had anticipated as Ann referenced in the planning assumption. I think to the last part of your question was oriented around the guide, what it assumes in the economy. Broadly speaking, as we stepped into the year, we recognize the fact that the year was going to be another dynamic year. The economy is a bit uncertain and a bit less stable. Stepping back in the current environment, we do not see dislocation in terms of our broader client portfolio, the overall enrollment levels remain relatively consistent. Employment levels, there's ebbs and flows of course, in terms of some of the headlines. But point one is, thus far through Q1, we see the economy holding up in terms of the nature in which it supports our portfolio. Two, we believe our full-year outlook contemplates in the ranges, importantly contemplate the dynamism of the market. And as Ann mentioned, both in her prepared remarks and previously, we believe that it's prudent to maintain our planning assumptions even though we had strength across the board in the first quarter of the year. So some more interest relative to the economy for sure, not seeing the impact in the first quarter, believe it's prudent at this point in time to maintain our planning assumptions. Thanks for your question.

Thank you. At this time, I'll turn the call over to David Cordani for closing remarks.

Thank you again for joining our call. Let me just reinforce a few points. One, we're confident in our ability to deliver our increased outlook for the full year. And to do that, we remain focused on those we serve, executing with discipline while we continue to innovate. Second, we will continue our leadership in improving healthcare, including delivering on the commitments we made earlier this quarter and the five that I highlighted in my prepared remarks. And third, I want to underscore that the progress we continue to make starts with and is fueled by the dedication, passion, and commitment of our colleagues around the world. We're proud of what we've achieved, and we're excited about the opportunities that are in front of us. Again, thanks for joining our call today.

Ladies and gentlemen, this concludes Cigna Corporation's first quarter 2025 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for ten business days following this call. You may access the recorded conference by dialing (800) 835-8067 or (203) 369-3354. There is no passcode required for this replay. Thank you for participating. We will now disconnect.